PRRT retreatment achieved high disease control in NETs, and longer benefit from first PRRT was tied to longer ...

Toni Choueiri, MD, discusses KEYNOTE-564 subgroup findings, adjuvant pembrolizumab after nephrectomy, overtreatment risks, and emerging biomarkers in renal cell carcinoma.

Explore how tissue biopsies and ctDNA blood tests reveal tumor genetics in metastatic breast cancer, with liquid biopsy ...

Chrisann Kyi, MD, discusses the 79.3% response rate with sofetabart mipitecan plus bevacizumab in platinum-sensitive ovarian cancer and phase 3 plans.

Targeted Onc connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Andrea Necchi, MD, discusses response-adapted treatment, higher complete response rates, and the potential to reduce the need ...

The planned study will evaluate the investigational PET imaging agent in approximately 280 patients with indeterminate brain ...

In OptimUM-01, first-line darovasertib plus crizotinib produced a 34.1% ORR and 21.1-month median OS in metastatic uveal ...

Personalized ctDNA monitoring guides adjuvant therapy and flags head and neck cancer relapse months early, showing high ...

At ESMO 2026, experts forecast how RAS inhibitors, new prostate cancer therapies, and IO combinations may reshape pancreatic, ...

The FDA has granted accelerated approval to amivantamab and hyaluronidase for advanced HNSCC based on the OrigAMI-4 trial.

Morana Vojnic, MD, MBA, explains how FET-PET imaging's FDA approval is enabling neuro-oncologists to identify ...